STUDY: Liquid Biopsy Could Guide Prostate Cancer Therapy, Complement PET Imaging
Prostate-specific membrane antigen (PSMA) expression on circulating tumor cells (CTCs) in men with metastatic castrate-resistant prostate cancer (mCRPC) is known to increase upon disease progression during treatment with abiraterone or enzalutamide. PSMA-targeted radioligand therapy has dramatically improved clinical outcomes in these cases.
"Recent prospective data from the PROPHECY trial set the stage for a liquid biopsy of CTCs to assess PSMA expression that could complement PSMA PET imaging and identify men more or less likely to benefit from drugs that target PSMA," says Andrew Armstrong, MD, MSc, PROPHECY PI and senior author of a new paper published this month in Clinical Cancer Research.
PROPHECY was funded in 2014 with a Prostate Cancer Foundation-Movember Challenge Award, and has resulted in eight publications so far, with more to come.
LEARN MORE (updated on May 3)
“A New Approach to Identifying Patients Who May Benefit from PSMA-Targeted Therapy” (Prostate Cancer Foundation, March 28, 2023)
WATCH: PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong (UroToday, April 21, 2023)
LEARN MORE in an interview with Dr. Armstrong by Cancer Therapy Advisor
(This was in relation to Dr. Armstrong's Oct. 2022 poster presentation on the same subject, ahead of publication)